$USPH

U S PHYSICAL THERAPY INC /NV (USPH): Entry into a Material Definitive Agreement

U S PHYSICAL THERAPY INC /NV (USPH) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. ITEM 1.01 Entry into a Material Definitive Agreement. On September 22, 2026, U.S. Physical Therapy, Inc.(the "Company") entered into a 45-month forward-starting interest rate swap agreement (the “Swap”) with Bank of America, National Association (“Bank of America”) with an initia

Original reporting
Published Sep 28, 2026, 9:08 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 28, 2026, 9:10 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$USPH
Neutral
high confidence
Mentioned
$USPH
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$USPHNeutralLow
01

Why it matters

The swap reduces exposure to rising rates, which could improve cash‑flow stability and support the stock.

02

Market read

A primary disclosure of a sizable interest‑rate hedge for a small‑cap healthcare firm.

03

What to watch

Potential covenant implications under the Credit Agreement and the credit rating impact.

Relevance 6/10Novelty 7/10Timing: post‑market filing

Background

US Physical Therapy Inc. disclosed a material definitive agreement to hedge interest rate risk on its term loan.

Company-level read

Ticker impact

$USPHNeutralHigh confidence
Context

USPH filed an 8‑K reporting a $170.6 million forward‑starting interest‑rate swap fixing its debt at 4.578% through 2031.

Expected impact

potential modest upside as the market prices in lower fixed‑rate cost versus variable SOFR exposure

Evidence & confidence

Fixed‑rate at 4.578% is below projected SOFR levels, likely viewed positively by investors.

Market effects

May influence other healthcare providers' financing strategies as rates rise.

Limited to USPH and its debt holders; no broad regional effect.

Minimal global impact; primarily a company‑specific financing disclosure.

Counterpoint

If SOFR falls sharply, the fixed rate could become a drag on earnings.

Key entities

  • U S Physical Therapy Inc.

    Issuer of the swap and subject of the 8‑K filing.

  • Bank of America, N.A.

    Administrative agent and swap counterparty.

Related articles

$USPHMed

US Physical Therapy (USPH) Taps A Global Finance Veteran As CFO

US Physical Therapy (USPH) appointed Nchacha Etta as CFO, effective September 1. Etta previously held CFO roles at Omnicell (OMCL) and Johnson & Johnson Vision. USPH reported Q2 2026 revenue of $214.1M, up 8.5%, but net income fell to $9.9M from $12.4M. The company reaffirmed full-year adjusted EBITDA guidance of $102M-$106M.

$USPHMedAI 8/10

USPH (USPH) Q2 2026 Earnings Call Transcript

US Physical Therapy (USPH) discussed its Q2 2026 results and hospital-affiliation rollout. The company said Q2 revenue rose 8.5% to $214M, PT revenue rose 8.4% to $182M, and visits increased 6.6% to 1.662M. Net rate was $107.59. It cited $3.2M higher self-insured health care costs and expects clinic transitions to continue into Q3.

$USPHMed

U S PHYSICAL THERAPY INC /NV (USPH): Results of Operations and Financial Condition

U S PHYSICAL THERAPY INC /NV (USPH) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 CONTACT: U.S. Physical Therapy, Inc. Jason Curtis, Interim Chief Financial Officer email: jcurtis@usph.com Chris Reading, Chief Executive Officer (713) 297-7000 Three Part Advisors Joe Noyons (817) 778-8424 USPH Reports Second Quarter 2026 Results, Reaffirms Full Yea

$NVDAHighAI 9/10

Nvidia Just Put a Record $150 Billion Behind Its Own Stock

Nvidia (NVDA) increased its share repurchase authorization by $150 billion, bringing its total buyback capacity to $235 billion through fiscal 2028. The company trades at 16.5 times forward earnings, its lowest multiple since 2015, despite forecasting 70% revenue growth for fiscal 2028. Nvidia ended the July quarter with $22.44 billion in cash. Shares rose nearly 2% Monday.

$VKTXMedAI 9/10

About $575 million came in for Viking Therapeutics, including $258.75 million in debt that can turn into shares.

Viking Therapeutics (VKTX) raised about $575M from upsized stock and convertible-note offerings, including $258.75M in 2.00% notes due 2032. The $35/share stock offering included 9,035,714 shares, with underwriters exercising options for 1,178,571 more. Net proceeds, after expenses, are estimated at $547.8M, earmarked for development programs and general corporate purposes.